by the British Pharmacopoeia Commission or another
recognised body; whenever possible they reflect the names
of the active ingredients. Prescribers should avoid creating
their own compound names for the purposes of generic
prescribing; such names do not have an approved definition
and can be misinterpreted.
Special care should be taken to avoid errors when prescribing
compound preparations; in particular the hyphen in the
prefix‘co-’should be retained. Special care should also be
taken to avoid creating generic names formodified-release
preparations where the use of these names could lead to
confusion between formulations with different duration of
action.6 Prescription writing BNFC 2018 – 2019
Prescription writing